Efficacy Findings from the RESONATE Trial

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the RESONATE trial, a phase III trial that compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the RESONATE trial, a phase III trial that compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.

Clinical Pearls:

  • The results of the study showed that the efficacy of ibrutinib was much superior to that of ofatubumab.
  • The study also showed response rates were significantly better with ibrutinib [ORR=42.6 vs 4.1% (P <0.0001), ORR+PR with lymphocytosis=62.6 vs 4.1%]
  • Progression-free survival was not yet reached in the ibrutinib arm but was about 8.1 months in the ofatumumab arm.

<<<

View more from the 2014 ASCO Annual Meeting